LMWH Dosing for DVT Treatment
Standard Treatment Dosing Regimens
- The American Society of Clinical Oncology recommends enoxaparin 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for acute DVT treatment 1, 2
- The National Comprehensive Cancer Network recommends dalteparin 200 units/kg subcutaneously once daily for initial treatment, with a maximum dose of 18,000 units 1, 2
Duration of Initial Treatment
- The American College of Chest Physicians recommends a minimum of 5-7 days of LMWH therapy before transitioning to oral anticoagulation 1
- The American Heart Association recommends continuing LMWH until INR reaches therapeutic range (2.0-3.0) for at least 24 consecutive hours if transitioning to warfarin 1
Special Population Dosing Adjustments
- The National Comprehensive Cancer Network recommends reducing enoxaparin to 1 mg/kg subcutaneously every 24 hours in patients with severe renal insufficiency (CrCl <30 mL/min) 2
- The American Society of Clinical Oncology recommends considering 0.8 mg/kg subcutaneously every 12 hours for enoxaparin in obese patients (BMI ≥40 kg/m²) 3
Comparative Efficacy
- The Journal of the National Comprehensive Cancer Network reports that all three LMWHs (enoxaparin, dalteparin, tinzaparin) demonstrate equivalent efficacy and safety for DVT treatment when used at recommended doses 2
Critical Monitoring Parameters
- The National Comprehensive Cancer Network recommends assessing renal function by measuring creatinine clearance before initiating therapy and periodically during treatment 2
- The American College of Chest Physicians recommends monitoring anti-Xa levels in patients with severe renal impairment (CrCl <30 mL/min), extreme obesity, or pregnancy 2
Common Pitfalls to Avoid
- The National Comprehensive Cancer Network warns against using standard doses in severe renal impairment without dose adjustment, particularly with enoxaparin 2, 3
- The American Society of Clinical Oncology advises against assuming all LMWHs are interchangeable, as they differ in molecular weight, half-life, and FDA approvals 2